Aldose reductase (alditol:NADP+ oxidoreductase, EC 1.1.1.21), an enzyme that converts glucose to sorbitol, the first step of the polyol pathway, has been implicated in secondary complications of diabetes, such as cataracts, retinopathy, neuropathy, and nephropathy. Aldose reductase inhibitors have been observed to prevent or delay the onset of these complications; however, more potent and specific inhibitors are needed. Development of new inhibitors necessitates a better understanding of the molecular structure of this protein.
ABSTRACT
Aldose reductase (alditol:NADP+ oxidoreductase, EC 1.1.1.21), an enzyme that converts glucose to sorbitol, the first step of the polyol pathway, has been implicated in secondary complications of diabetes, such as cataracts, retinopathy, neuropathy, and nephropathy. Aldose reductase inhibitors have been observed to prevent or delay the onset of these complications; however, more potent and specific inhibitors are needed. Development of new inhibitors necessitates a better understanding of the molecular structure of this protein.
To elucidate the structure-function relationships of aldose reductase and to develop methods of regulating this enzyme, large and homogeneous quantities of rat lens aldose reductase have been expressed in bacterial cells. A construction of the complete coding sequence and 3' untranslated region for rat lens aldose reductase was assembled in the expression vector pKK233-2 (Pharmacia). This construction expresses an active enzyme that has been purified and demonstrates kinetic, immunological, and inhibitory properties similar to rat lens aldose reductase.
Aldose reductase (alditol:NADP+ oxidoreductase, EC 1.1.1.21) is the first enzyme in the polyol pathway. It reduces glucose to sorbitol, which can then be converted to fructose by sorbitol dehydrogenase (EC 1.1.1.14). The accumulation of sorbitol has been linked to diabetic complications affecting the nerves, lens, retina, and kidneys (1) (2) (3) (4) . In hyperglycemia, the accumulation of intracellular sorbitol causes an influx of water, which results in swelling and eventual loss of cellular integrity (3, 5) . The regulation and expression of aldose reductase have been examined by a number of investigators in the kidney (6) (7) (8) (9) (10) , in the lens (11) (12) (13) , and in the placenta (14, 15) .
The involvement of aldose reductase in the secondary complications of diabetes has led to the development of a number of aldose reductase inhibitors. Inhibition of aldose reductase has been shown to be effective in reducing diabetic complications (16) (17) (18) (19) (20) (21) . However, better knowledge of the detailed structure of aldose reductase may aid in the development of more specific, potent inhibitors.
Studies on the regulatory properties, potential inhibitor sites, and overall structure of aldose reductase requires large amounts of purified enzyme. Here we report the construction of the complete coding sequence for rat lens aldose reductase in a bacterial expression vector and the subsequent production, purification, and characterization of this recombinant enzyme.
MATERIALS AND METHODS
Plasmid Construction. A full-length DNA sequence corresponding to the coding region and the 3' untranslated sequences of the rat lens aldose reductase cDNA was constructed in the expression vector pKK233-2 (Pharmacia) (Fig. 1) . The cDNA clone 4B (22) was digested with Ban I and the 990-base-pair (bp) fragment was purified from a 4% polyacrylamide gel. An oligonucleotide was synthesized (Applied Biosystems DNA synthesizer, model 380B) and purified (from a 4% polyacrylamide gel) that corresponded to the 56 bp of the 5' coding sequence (from the ATG initiation codon to the Ban I site at the 3' end) plus 10 bp that included a BamHI site and a HindIII overhang site on the 5' end of the oligonucleotide. The oligonucleotide was ligated to the Ban I fragment of 4B and gel purified from a 7% agarose gel using NA45 nitrocellulose according to manufacturer's instruction (Schleicher & Schuell) . This new HindIII fragment was ligated into pBSII KS-(Stratagene). In this construction there was anomalous cloning at the 3' end of the construct. The oligonucleotide did not ligate to the 3' end of the 4B fragment, and the Ban I site from the 3' end of 4B and the HindIII site from the vector ligated together destroying both recognition sequences (Fig. 1, 0 centrifuged (Sorvall RC6000; 2000 x g) and washed twice in 20 mM phosphate buffer containing 7 mM 2-mercaptoethanol and 0.5 mM EDTA (pH 7.5). The cell pellet was resuspended in 0.5 ml of the same buffer plus 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma) and sonicated (five bursts, 2-to 3-sec pulses at 50% power) to break the bacterial cell walls. The Bradford protein assay (Bio-Rad) was performed to determine protein concentration using bovine serum albumin as a standard. Two micrograms of total protein was separated on the Phastgel system (Pharmacia) according to manufacturer's instructions. The protein gels were either stained with Coomassie blue or transferred to nitrocellulose for immunoblot analysis.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. The nitrocellulose filters were incubated with a rat lens aldose reductase antibody (1:250 dilution) (25) overnight at 4°C after 30 min in a 0.2% milk blocking solution. To visualize the antigen-antibody complex the Vectastain ABC kit was used according to manufacturer's instructions (Vector Laboratories). Recombinant aldose reductase protein was compared to purified rat kidney aldose reductase and whole rat lens homogenate.
Protein Purification. E. coli DH5a harboring construct pKKARX33 was grown in 500 ml of Luria broth plus 50 ,ug of ampicillin per ml overnight. The cells were centrifuged (GS3; 8000 x g) and washed twice in 20 mM phosphate buffer containing 7 mM 2-mercaptoethanol and 0.5 mM EDTA (pH 7.5). The cell pellet was resuspended in 5 ml of the same buffer plus 1 mM PMSF and split into five tubes for sonication (10 bursts for 3-5 sec at 50% power). The sonicated samples were pooled and protein concentration was determined by the Bradford protein assay (Bio-Rad). The sample centrifuged at 10,000 x g for 15 min and the recombinant protein was then purified from the supernatant as described (26) . Briefly, the supernatant was applied to a Sephadex G-75 column and eluted with the same phosphate buffer as above. Fractions collected (about 10 ml) were assayed for NADPH reducing activity with DL-glyceraldehyde as substrate. Those fractions containing activity were applied to a Matrex gel orange A column (Amicon) equilibrated with the same phosphate buffer. After washing with 300 ml of the phosphate buffer followed by 200 ml of 10 mM imidazole buffer (pH 7.6) containing 7 mM 2-mercaptoethanol, the recombinant protein was eluted with 100 ml of the imidazole buffer containing 0.1 mM NADPH and collected in 150 drop fractions. Fractions containing enzyme activity were applied to a Mono P column (Pharmacia) and eluted with Polybuffer 74 (Pharmacia) containing 7 mM 2-mercaptoethanol. The purification process was also performed using the DH5a cells as a control.
Aldose Reductase Activity and Inhibition. Aldose reductase activity was photometrically determined by monitoring the decrease in absorbance of NADPH at 340 nm using 10 mM DL-glyceraldehyde, 10 mM D-xylose, 10 mM D-glucuronate, 10 mM D-galactose, or 10 mM D-glucose as substrates. One unit of activity was defined as the activity consuming 1 Amol of NADPH per min at 220C.
Inhibition of aldose reductase by Sorbinil (Pfizer), AL 1576 (Alcon), Tolrestat (Wyeth-Ayerst), and Ponalrestat (ICI) was determined with DL-glyceraldehyde as substrate as described (27) .
Recombinant aldose reductase activity and inhibition were compared to activity and inhibition of purified rat lens aldose reductase.
RESULTS
Two constructions were made that correspond to the fulllength DNA coding sequence and 3' untranslated region of the rat lens aldose reductase (pKKARX28 and pKKARX33) (outlined in Fig. 1 and Materials and Methods). In addition, two constructs were made that contained a large portion of the cDNA in reverse orientation with respect to the trc promoter (pKKARX22 and pKKARX36) and one construct was made that contained only the first 303 bp of the coding sequence (pKKNP1). These constructions were introduced into E. coli DH5a where the trc promoter is constitutively expressed. The constitutive expression of aldose reductase did not appear to affect bacterial cell growth. The blot analysis of the various constructs showed that only pKKARX33 and pKKARX28 had an additional protein that reacted with the rat lens aldose reductase antibody (Fig. 2) . This protein had an approximate Mr of 35,000 (Fig. 2B, lanes   2 and 3) , which is similar to purified rat kidney and whole rat lens aldose reductase (Fig. 2B, lanes 5 and 6) endogenous inhibition of the enzyme in the sonicated cells, either of which is removed following gel filtration. Purification ofthe recombinant protein on Mono P produced only one peak containing enzyme activity (Fig. 3) , in contrast to the one major peak plus several smaller peaks observed with rat lens aldose reductase (26) . The purified protein appeared as a single band on SDS/PAGE immediately upon purification. However, upon storage of the protein a doublet was observed. The second band was observed with the recombinant protein as well as the purified aldose reductase from kidney. The recombinant purified protein reacted with antibodies raised against rat lens aldose reductase (Fig. 3 Inset, lanes 1  and 4) .
The relative activities of the pKKARX33 crude cell homogenate and purified recombinant protein were tested with various substrates and compared to that of purified rat lens aldose reductase (Table 2) , with the relative activity of DL-glyceraldehyde at 100%. The activity profiles ofpKKARX- ( 3) The relative specificities of various substrates for aldose reductase were compared for the recombinant aldose reductase (pKKARX33) and purified rat lens aldose reductase (RLAR). The specific activity of DL-glyceraldehyde was set at 100%. Values are given as mean ± SD, with the number of samples in parentheses. The total cell homogenate (crude) and the purified recombinant aldose reductase from the Mono P column (pure) were examined. (NaCl) . This is consistent with aldose reductase activity (28) .
The recombinant enzyme was also inhibited by a series of aldose reductase inhibitors ( Table 3) . As noted by their IC50 values, these inhibitors produced similar inhibition in the recombinant protein and rat lens aldose reductase.
DISCUSSION
Mounting experimental evidence links the aldose reductaseinitiated accumulation of polyol with the onset of diabetic complications (3). Furthermore, these studies suggest that aldose reductase inhibitors represent a pharmacologicallyderived approach for the treatment of diabetic complications that is independent of the control of blood sugar levels. Preliminary clinical trials, however, suggest that more potent and selective aldose reductase inhibitors are required. To facilitate the development ofadditional inhibitors, knowledge of the inhibitor binding site(s) and the mechanism of action of these inhibitors is required. Such studies utilize large amounts of purified enzyme. Presently, significant amounts of animal tissue must be utilized in order to obtain the large amounts of purified enzyme necessary. However, the development of recombinant DNA technology provides an alternative to the use of large quantities of animal tissue.
The construction of a rat lens aldose reductase DNA coding sequence in an expression vector has yielded an abundant, enzymatically active enzyme in bacterial cells that is immunologically detectable by rat lens aldose reductase antibodies. This recombinant enzyme was purified to apparent homogeneity, demonstrated relative substrate specificities, and was inhibited by aldose reductase inhibitors similar to that of rat lens aldose reductase. The recombinant enzyme has a molecular weight similar to rat lens and rat kidney aldose reductase on SDS/PAGE and immunoblotting. Together, these data strongly suggest that the recombinant enzyme produced in these DH5a cells is rat lens aldose reductase.
The bacterial cells producing recombinant aldose reductase represent an approach for obtaining large quantities of enzyme that can be purified to apparent homogeneity. In these cells, aldose reductase constitutes -'4% of the total proteins. The availability of this enzyme in abundant quantities by recombinant methods will facilitate studies on the characterization of the key elements of the substrate, NADPH, and inhibitor binding sites through the use of site-directed mutagenesis studies. Moreover 
